Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has updated its facility name and location to Milan, Italy, and has added specific drug names, including cabozantinib and durvalumab, while removing several related medical topics and previous location details.SummaryDifference1%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
- Check49 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.1%
Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.